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Pifferences in the Management
nd Prognosis of Women and Men
ho Suffer From Acute Coronary Syndromes
onia S. Anand, MD, PHD, FRCPC,* Chang Chun Xie, MSC, PHD,* Shamir Mehta, MD, MSC, FRCPC,*
aria Grazia Franzosi, BIOL SCD,† Campbell Joyner, MD, FRCPC,‡ Susan Chrolavicius, BSC,*
eith A. A. Fox, MD, FRCP,§ Salim Yusuf, DPHIL, FRCPC,* for the CURE Investigators
amilton and Toronto, Ontario, Canada; Milan, Italy; and Edinburgh, United Kingdom
OBJECTIVES The purpose of this research was to determine if sex and gender differences in the
management of acute coronary syndromes (ACS) are associated with differences in prognosis
after ACS.
BACKGROUND Previous investigators have reported sex/gender differences in the management of patients
with ACS, but the impact of these differences on prognosis is unclear.
METHODS We analyzed data from the Clopidogrel in Unstable Angina to Prevent Recurrent Events
(CURE) trial, which enrolled 4,836 women and 7,726 men with ACS. Patients were
classified into risk strata using the Thrombolysis In Myocardial Infarction (TIMI) score.
RESULTS Women underwent fewer invasive procedures including angiography, angioplasty, and
coronary artery bypass graft (CABG) surgery (47.6% vs. 60.5%; p  0.0001) compared to
men. No significant differences in cardiovascular death, myocardial infarction (MI), or stroke
were observed (9.8% vs. 10.9%; p  0.04), although women were more likely than men to
develop refractory ischemia and to be rehospitalized for chest pain during follow-up (16.6%
vs. 13.9%; p  0.0001). These differences were particularly evident among TIMI high-risk
women. A significant interaction between TIMI risk and gender for the outcome of refractory
angina and rehospitalization for angina was present.
CONCLUSIONS Compared to men, high-risk women with ACS undergo less coronary angiography,
angioplasty, and CABG surgery, and while they do not have higher incidence cardiovascular
death, recurrent MI, or stroke, they suffer an increased rate of refractory ischemia and
rehospitalization. All high-risk women and men with ACS should receive optimal medical
management, and be considered for coronary angiography with possible revascularization if
their coronary anatomy warrants it. (J Am Coll Cardiol 2005;46:1845–51) © 2005 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.05.091American College of Cardiology Foundation
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toronary heart disease is the single leading cause of death
nd is a significant cause of morbidity among women in
orth America (1). Acute coronary syndromes (ACS)
epresent a continuum of acute myocardial ischemia and
See page 1852
nclude acute transmural myocardial infarction (MI) with
T-segment elevation, MI without ST-segment elevation
NSTEMI), and unstable angina (UA). On its own,
STEMI/UA is a significant cause of morbidity and
ortality and is associated with a 10% to 15% rate of death
r MI at one year (2); NSTEMI/UA accounts for more
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niversity. Dr. Yusuf is a recipient of a Canadian Institutes of Health Research Senior
cientist Award and holds a Heart and Stroke Foundation of Ontario Research Chair.o
Manuscript received January 27, 2005; revised manuscript received May 3, 2005,
ccepted May 22, 2005.han 1.5 million hospitalizations annually in the U.S., and
early 50% of these admissions occur among women (1).
Over the past decade, investigators have reported on
ex/gender differences among patients with ACS (3–7).
his research is fuelled by beliefs that biological differences
nfluence the pathogenesis of coronary artery disease (CAD)
nd the response to medical therapies (sex differences), as
ell as a perception that women’s access to medical therapy
nd cardiac procedures such as cardiac catheterization,
ngioplasty, and bypass surgery is inappropriately restricted
gender differences) (3,8,9). Prior investigators have re-
orted that women with ACS receive fewer invasive cardiac
rocedures compared to men, although it remains unclear if
his affects their prognosis after ACS. To address this issue,
e compared the management of ACS patients among
omen and men to determine if sex/gender differences were
ssociated with prognosis after ACS in the Clopidogrel in
nstable Angina to Prevent Recurrent Events (CURE)
rial, which enrolled 4,836 women and 7,726 men (10).
ETHODS
e conducted a post-hoc analysis of data from the CURE
rial. Details of the CURE trial have been reported previ-
usly (10). Briefly, the trial enrolled men and women who
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Sex/Gender Differences in ACS Management and Prognosis November 15, 2005:1845–51resented within 24 h of symptoms onset with ACS,
ncluding UA and NSTEMI as previously described (10).
atients with contraindications to antithrombotic/
ntiplatelet therapy, who were at high risk of bleeding, who
ad severe heart failure (class IV), who had an ongoing
ong-term need for oral anticoagulants, and who had per-
utaneous transluminal coronary angioplasty (PTCA)/stent,
r coronary artery bypass graft (CABG) within three
onths before randomization were excluded. Patients were
ecruited between December 1998 and September 2000
rom 482 centers in 28 countries. The protocol was ap-
roved by the institutional review board of each hospital,
nd all patients provided written informed consent.
linical outcomes. All primary and secondary efficacy and
afety outcomes for the trial were adjudicated by an inde-
endent panel of clinicians who were blinded to the treat-
ent allocation. Cardiovascular death was defined as any
eath for which there was no clearly documented nonvas-
ular cause. Myocardial infarction was defined as the pres-
nce of at least two of the following: ischemic chest pain;
levation of the serum levels of cardiac markers or enzymes
troponin, creatine kinase, creatine kinase-MB isoenzyme,
r other cardiac enzymes) to at least twice the upper limit of
he normal, or three times the upper limit of normal within
8 h after percutaneous coronary intervention; and electro-
ardiographic (ECG) changes compatible with infarction.
troke was defined as a new focal neurologic deficit of
ascular origin lasting more than 24 h. Refractory angina
as defined using stringent criteria, specifically a patient
ust have severe anginal chest pain in the hospital lasting
ore than 5 min associated with new ECG changes while
he patient was receiving optimal medical therapy leading to
n additional intervention such as thrombolytic therapy,
ardiac catheterization, the insertion of an intra-aortic
alloon pump, coronary revascularization, or transfer to a
eferral hospital for an invasive procedure by midnight of
he next calendar day. Refractory ischemia after hospital
ischarge was defined by rehospitalization for UA lasting
or at least 24 h and associated with ischemic ECG changes
10). Invasive cardiac procedures including coronary angiog-
aphy, PTCA, and CABG since randomization were also
Abbreviations and Acronyms
ACS  acute coronary syndrome
CABG  coronary artery bypass graft
CAD  coronary artery disease
CURE  Clopidogrel in Unstable Angina to Prevent
Recurrent Events
MI  myocardial infarction
NSTEMI  non–ST-segment elevation myocardial
infarction
PTCA  percutaneous transluminal coronary
angioplasty
TIMI  Thrombolysis In Myocardial Infarction
UA  unstable anginaecorded. Angiographers recorded which vessels were sig- cificantly diseased, and the corresponding percent stenoses.
tenoses in significantly sized branches defined as 2 mm
n diameter were recorded under the major vessel from
hich they originated. Significant CAD was defined as
riple-vessel disease (defined as 50% stenosis in the
roximal or mid/distal left anterior descending, circumflex,
nd right coronary artery) or left main stenosis 50%.
ollow-up assessments occurred at discharge, at 1 month,
nd then every 3 months for a maximum of 12 months or a
inimum of 3 months (mean 9 months).
tatistical considerations. Baseline characteristics, medi-
al and coronary interventions, and clinical outcomes were
ompared between women and men. For comparisons of
ontinuous variables, linear regression was used, and for
omparisons of categorical values, logistic regression was
sed. Patients were stratified by risk status using the
reviously validated Thrombolysis In Myocardial Infarction
TIMI) risk score, which includes clinical, ECG criteria,
nd biochemical factors (11). Multivariable models were
onstructed to determine the predictive value of gender and
rocedure use on clinical outcomes, with gender, TIMI
core, and the interaction between gender  TIMI score
sed as independent variables. Comparisons between
omen and men were adjusted for differences in baseline
actors, which influence clinical outcomes including age,
iabetes, smoking status, history of cardiovascular disease,
ardiac enzyme/troponin abnormality, geographic region
because intervention rates vary significantly by region) (12),
nd treatment allocation (i.e., clopidogrel vs. placebo). To
void spurious findings in the face of multiple statistical
omparisons, statistical significance was declared when p
alues were 0.01.
ESULTS
aseline characteristics. A total of 12,562 patients were
nrolled in the trial: 4,836 women and 7,726 men. Women
ere older, and had higher age-adjusted rates of diabetes,
ypertension, and elevated cholesterol compared to men.
en were more likely to be smokers, and have a prior
istory of MI, peripheral arterial disease, and stroke com-
ared to women. The average time from symptom onset to
resentation was similar, although women were more likely
o have an abnormal ECG at presentation, and men were
ore likely to have abnormal cardiac enzymes. Approxi-
ately 15% of women and men were classified as “high-
isk” by the TIMI score (Table 1).
edical treatments received. At hospital presentation, no
ifferences in the use of aspirin, statins, or beta-blockers
etween women and men were observed, although women
ere more likely to be taking angiotensin-converting en-
yme inhibitors, and 7% of women were taking hormone
eplacement therapy. During the initial hospitalization, the
se of aspirin, statins, beta-blockers, and angiotensin-
onverting enzyme inhibitor medications increased signifi-
antly among all patients. However, during the hospitaliza-
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November 15, 2005:1845–51 Sex/Gender Differences in ACS Management and Prognosision and at the time of discharge, women were less likely to
e treated with beta-blockers compared to men (Table 2).
his difference persisted throughout the follow-up period
data not shown).
nvasive procedures. Coronary angiography was per-
ormed among significantly fewer women compared to men
uring the initial hospitalization (adjusted rates: 25.4% vs.
9.5%; p 0.0001), and over the course of the nine months
f follow-up (14.0% vs. 16.0%, p  0.006) (Table 3).
mong those who had angiography, women were more
ikely to have normal coronary vessels (26.7% vs. 13.2%, p
.0001), and less likely to have significant CAD (34.9% vs.
4.7%, p  0.00001) compared to men. Subsequently,
Table 1. Baseline Characteristics*
Number
Age, yrs (SD)
BMI, kg/m2 (SD)
Diabetes (%)
Hypertension (%)
Current or former smoker (%)
Hypercholesterolemia (%)
History of MI (%)
History of PAD (%)
History of stroke (%)
Prior PTCA with or without stent (%)
Prior CABG surgery (%)
Other evidence of CAD including chronic stable ang
History of any CVD† (%)
Time from symptoms onset to hospital presentation
Abnormal ECG at presentation‡ (%)
Cardiac enzyme or troponin abnormality (%)
Congestive heart failure on admission (%)
Length of initial hospitalization (days)
TIMI risk score (mean  1.77)—low§
TIMI risk score (mean  3.49)—moderate§
TIMI risk score (mean  5.22)—high§
*Age-adjusted mean and proportions using linear or logistic
stroke, or PAD; ‡defined as significant ST-segment abnorma
elevation2 mm) or T-wave inversion; §not age-adjusted as
Infarction (TIMI) score.
BMI  body mass index; CABG  coronary artery bypas
disease; MI  myocardial infarction; PAD  peripheral
angioplasty.
Table 2. Medication Use
Pres
Aspirin (%)
Women
Men
HMG-CoA reductase inhibitor %)
Women
Men
Beta-blocker (%)
Women
Men
ACE inhibitor (%)
Women
Men
Adjusted for age, diabetes, hypertension, smoking status, h
cardiovascular disease. Women versus men: *p  0.001, †p  0.01
ACE  angiotensin-converting enzyme.ignificantly fewer women underwent PTCA or CABG
urgery, although among women and men who were iden-
ified as having significant CAD on angiography, the
roportion of patients who underwent PCTA or CABG
as similar (69.2% vs. 72.7%, p  0.10) (Table 3). No
ifference in the incidence of cardiovascular death, recurrent
I, or stroke was observed at 30 days (4.4% vs. 4.9%, p 
.23) or at the end of follow-up (approximately 9 months)
9.7% vs. 11.1%, p  0.04) between women and men.
owever, compared to men, significantly more women had
efractory ischemia during the index hospitalization and
ere rehospitalized for UA during the course of follow-up
16.6% vs. 13.9%, p  0.0002) (Table 3).
Women Men Significance
4,836 7,726
66.5 (10.7) 62.7 (11.4) 0.0001
27.6 (4.5) 27.3 (3.9) 0.0001
24.6 20.9 0.0001
68.8 53.0 0.0001
37.4 76.4 0.0001
48.7 44.3 0.0001
23.9 36.9 0.0001
5.8 9.0 0.0001
3.0 4.1 0.0008
7.2 11.5 0.0001
6.8 13.3 0.0001
%) 46.2 43.8 0.01
59.0 63.7 0.0001
14.0 14.2 0.17
95.3 92.8 0.0001
18.8 29.3 0.0001
1.2 1.3 0.43
10.7 10.1 0.0001
26.2 26.0 0.77
58.3 58.0 0.74
15.5 16.0 0.43
ssion; †defined as prior MI, PTCA, CABG, other CAD,
epression 1 mm, elevation 1 mm, transient ST-segment
ncluded in the definition of the Thrombolysis In Myocardial
ing; CAD  coronary artery disease; CVD  cardiovascular
al disease; PTCA  percutaneous transluminal coronary
ion In-Hospital Discharge
99.7 95.7
99.8 95.6
45.8 48.2
47.3 50.0
77.0† 68.4*
79.6 73.1
50.3 46.5
51.2 47.8
olesterolemia, prior myocardial infarction, prior history ofina (
(h)
regre
lity (d
age is i
s graftentat
65.8
66.6
25.3
25.4
58.1
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41.3†
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Sex/Gender Differences in ACS Management and Prognosis November 15, 2005:1845–51isk stratification. Patients were stratified into low-,
ntermediate-, and high-risk categories using the previously
alidated TIMI risk score. As expected, with increasing risk,
he rate of cardiovascular death, MI, stroke, and refractory
able 3. Procedures and Clinical Outcomes
ngiography (overall) (%)
In-hospital (%)
Out of hospital (%)
o diseased vessels (%) 4
ignificant coronary artery disease by angiography
(triple-vessel disease or left main 50%) (%)
6
ngioplasty or CABG (%)
ngioplasty or CABG among patients with
significant coronary artery disease (%)
451
V death, MI, stroke at 30 days (%)*
V death, MI, stroke at end of follow-up (%)*
efractory angina or rehospitalization for angina (%)*
VD, MI, stroke, refractory angina, or
rehospitalization (%)*
Adjusted for: age, diabetes, smoker, history of any cardiovascular (CV) disease, card
tenosis as definition for “diseased.” *Triple-vessel disease 50% stenosis in proxima
xcluding left main 50%. Region  North America, South America/Mexico, Wes
BMI  body mass index; CABG  coronary artery bypass grafting; CAD  cor
eripheral arterial disease; PTCA  percutaneous transluminal coronary angioplasty
able 4. Gender Differences in Invasive Procedures and Clinical
TIMI Low TIMI In
ngiography
Women 538/1,268 (42.4%) 1,042/2,8
Men 987/2,008 (49.2%) 2,074/4,4
ignificant coronary artery disease on
angiography
Women 95/538 (17.6) 383/1,0
Men 289/987 (29.2) 997/2,0
TCA or CABG among those with
significant coronary disease
Women 73/95 (76.8) 265/3
Men 235/289 (81.3) 725/9
efractory (in-hospital) or
rehospitalization for chest pain
(adjusted for treatment
allocation, region)
Women 148/1,268 (11.7%) 463/2,8
Men 231/2,008 (11.5%) 679/4,4
V death, MI, stroke by end of
follow-up (adjusted for
treatment allocation, region)
Women 55/1,268 (4.3%) 288/2,8
Men 107/2,008 (5.3%) 486/4,4
V death, MI, stroke or refractory
ischemia (adjusted for treatment
allocation, region)
Women 193/1,268 (15.2%) 681/2,8
Men 322/2,006 (16.0%) 1,056/4,4ABG  coronary artery bypass graft surgery; CV  cardiovascular; MI  myocardial infa
IMI  Thrombolysis In Myocardial Infarction.oronary ischemia increased significantly among all patients;
urprisingly, however, the rate of coronary angiography did
ot differ. Across all risk strata, angiography rates were
ignificantly lower among women compared to men.
en Men Significance
6 7,726
4 45.5 p  0.0001
4 29.5 p  0.0001
0 16.0 p  0.006
6.7) 480 (13.2) p  0.00001
4.9) 1,621 (44.7) p  0.00001
8 40.4 p  0.0001
69.2%) 1,178/1,621 (72.7%) p  0.10
4 4.9 p  0.23
7 11.1 p  0.04
6 13.9 p  0.0002
6 22.5 p  0.19
yme/troponin abnormality, region, and treatment allocation. Use of 50% cut-off for
id-/distal left anterior descending coronary artery, circumflex, right coronary artery,
urope, Eastern Europe, Australia/New Zealand, South Africa.
artery disease; CVD  cardiovascular disease; MI  myocardial infarction; PAD 
omes by TIMI Risk
diate TIMI High Significance Women vs. Men
.0%) 286/750 (38.1%) p  0.001 within each risk strata
.3%) 564/1,239 (45.5%)
.7) 174/286 (60.8) p  0.00001 in low and intermediate
strata, p  0.68 in high stratum
.1) 335/564 (59.4)
.2) 113/174 (64.9) p  0.31 for low-, p  0.17 for
intermediate-, p  0.97 for high-risk
.7) 218/335 (65.1)
.4%) 179/750 (23.9%) p  0.73 for low-, p  0.02 for
intermediate-, p  0.0001 for high-risk
stratum, p interaction  0.0001
.2%) 189/1,239 (15.3%)
.2%) 146/750 (19.5%) p  0.11 for low-, p  0.35 for
intermediate-, p  0.40 for high-risk
.8%) 219/1,239 (17.8%)
.2%) 273/750 (36.4%) p  0.54 for low-, p  0.24 for
intermediate-, p  0.0009 for high-risk
.6%) 360/1,239 (29.1%)Wom
4,83
39.
25.
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November 15, 2005:1845–51 Sex/Gender Differences in ACS Management and Prognosismong low- and moderate-risk patients, women were less
ikely to have significant CAD on angiography compared to
en, whereas among high-risk patients, women had a
imilar proportion of “significant” coronary disease com-
ared to men (60.8% vs. 59.4%; p  0.68), and the rates of
TCA or CABG surgery among those with significant
AD were similar (64.9% vs. 65.1%; p  0.97) (Table 4).
he incidence of cardiovascular death, MI, stroke was not
ncreased among high-risk women compared to men (19.5%
s. 17.8%; p  0.40), but the incidence of refractory angina
igure 1. High-risk acute coronary syndrome patients. Open bars wome
ndicates triple-vessel disease or left main disease. *p  0.005. CABG 
yocardial infarction; PTCA  percutaneous transluminal coronary angio
igure 2. Refractory ischemia and rehospitalization by gender and Throm-
olysis In Myocardial Infarction (TIMI) risk. Adjusted for treatmentf
llocation and region. Solid line  women; dashed line  men. *Note: p
or interaction between TIMI risk and gender  0.001.nd rehospitalization for chest pain during follow-up was
ignificantly higher (23.9% vs. 15.3%; p  0.0001) (Fig. 1,
able 4). A significant interaction between the TIMI risk
trata and gender for the outcome of refractory angina and
ehospitalization was present (pinteraction  0.0001) (Fig. 2).
ISCUSSION
ur findings demonstrate that, after ACS, women are less
ikely to undergo angiography, PTCA, and CABG com-
ared to men, and while they have no differences in
ardiovascular death, MI, or stroke, they do suffer an
ncreased rate of refractory angina and rehospitalization for
A. This is especially true among high-risk women.
Our study is consistent with the results of previous
nvestigators who have reported that, compared with men,
omen with NSTEMI/UA are generally older, have more
omorbidities at the time of presentation, and undergo
ewer coronary interventions (13–15). However, the lower
ate of invasive cardiac procedures has not been convincingly
inked to differences in prognosis after the acute coronary
pisode, nor has it been linked to any systematic biases
5,7,13–15). Explanations for the differences in the rates of
oronary invasive procedures between women and men are
ultiple, and include differences in the presentation of ACS
e.g., reporting of typical versus atypical symptoms) (3),
atient preferences to undergo invasive cardiac procedures
8,16–18), and physician practices in the referral of women
lid bars men. Significant coronary artery disease (CAD) by angiography
nary artery bypass graft surgery; CVD  cardiovascular disease; MI 
y.n; soor cardiac catheterization (8).
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Sex/Gender Differences in ACS Management and Prognosis November 15, 2005:1845–51Our analysis differs from previous reports because it
ncludes the largest number of women enrolled into an ACS
linical trial to date (n  4,836); it includes patients from a
road representation of countries (e.g., North and South
merica, and Europe), and it examines procedure use and
rognosis according to the TIMI risk score. Surprisingly in
he CURE trial cohort, the decision to perform angiography
as not linked to the risk status of patients, and in all risk
roups women were less likely to have angiography. Among
omen who did undergo angiography, those in the low- or
oderate-risk TIMI categories were less likely to have
ignificant CAD, whereas women in the high-risk stratum
ad a similar proportion of significant CAD compared to
en. The lower angiography rates among high-risk women
ikely “underidentified” women with significant CAD who
equired coronary revascularization, and this difference in
ngiography may be particularly important to address given
hat high-risk women suffered a significantly higher inci-
ence of refractory angina and rehospitalization for ACS
ver the long-term compared to men (Fig. 2). However, it
s not clear from existing clinical trials whether an early
nvasive strategy is as beneficial in reducing hard clinical
utcomes such as death and MI among women as it is
mong men.
Recently, subgroup analyses of the Fragmin and Fast
evascularization during InStability in Coronary artery
isease (FRISC)-2 (n 749 women) (13) and Randomized
ntervention Trial of unstable Angina (RITA)-3 (n  648
omen) (14) randomized clinical trials reported worsened
utcomes among women who underwent invasive manage-
ent of ACS, which has raised doubt as to whether the
anagement approach toward women and men should be
imilar. The results from these trials conflict with the more
ecent Treat Angina With Aggrastat and Determine Cost
f Therapy With Invasive or Conservative Strategy
TACTICS)-TIMI 18 trial report (n  757 women) in
hich women appeared to benefit as much as men from an
arly invasive strategy (32% risk reduction in death and MI;
 0.02), especially women with elevated troponin T levels
t baseline (15). This is supported by the Can Rapid Risk
tratification of Unstable Angina Patients Suppress Adverse
utcomes with Early Implementation of the ACC/AHA
uidelines Quality Improvement Initiative (CRUSADE)
rospective registry of 17,926 ACS patients from 248 U.S.
ospitals in which women who were 14% less likely to
eceive early invasive management after ACS had a signif-
cantly higher in-hospital mortality (no early invasive vs.
arly invasive: 8.9% vs. 4.7%) (19). Whether the differences
bserved across studies reflect differences in the clinical
haracteristics of women, differences in health system ap-
roaches to the treatment of men and women with ACS,
etrospective methodology, or the unreliable nature of sub-
roup analyses remains unclear. Despite the fact that our
rial included the largest number of women enrolled into an
CS trial to date (n  4,836), an examination of theeasons for sex/gender differences is limited because detailednformation regarding presentation, symptoms, center char-
cteristics (i.e., cath lab facilities), changes in risk factors
nd medication use over time, referral patterns, and patient
references was not collected. The only way to definitively
etermine if differences in early intervention rates between
omen and men with NSTEMI/UA, including those at
igh risk, are associated with differences in their long-term
rognosis, especially hard outcomes such as cardiovascular
eath, MI, and stroke, is to randomize women to different
ntervention strategies and collect long-term follow-up data.
The medical management of men and women with ACS
ppears to be equivalent as the use of aspirin, statins,
eta-blockers, and angiotensin-converting enzyme inhibi-
ors increased significantly during the initial hospitalization
mong all patients in our trial, although significantly fewer
omen were prescribed beta-blockers at the time of dis-
harge compared to men. This may be appropriate given
hat fewer women had suffered from a previous MI. More
omen were taking angiotensin-converting enzyme inhib-
tors at the time of admission, which is likely due to the
reater proportion of women with diabetes, who were on
ngiotensin-converting enzyme inhibitors for renal protec-
ion. In the CURE trial, the risk reduction with clopidogrel
as not significantly heterogeneous between women com-
ared to men. This is consistent with data for a number of
ther pharmacologic treatments that indicate that antiplate-
ets, beta-blockers, angiotensin-converting enzyme inhibi-
ors, and lipid-lowering therapies clearly reduce the risk of
uture vascular events by approximately a quarter in both
omen and men (20). Therefore, as the incidence of
ardiovascular death, MI, and stroke was between three to
our times greater among high-risk patients compared to
ow-risk patients in our trial, it appears especially important
hat all high-risk patients—men and women—receive opti-
al medical management, and are considered for coronary
ngiography with possible revascularization when their cor-
nary anatomy warrants it (15,20,21).
onclusions. Compared to men, high-risk women with
CS undergo less coronary angiography, angioplasty, and
ABG surgery, and while they do not have higher inci-
ence CV death, recurrent MI, or stroke, they suffer an
ncreased rate of refractory ischemia and rehospitalization.
ll high-risk women and men with ACS should receive
ptimal medical management, and be considered for coro-
ary angiography with possible revascularization if their
oronary anatomy warrants it.
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